Medinice S.A (ICE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medinice S.A (ICE) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-1.77 Million ≈ $-487.13K USD) by net assets (zł88.12 Million ≈ $24.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ICE equity to assets ratio to measure how much of total assets are equity-financed.
Medinice S.A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Medinice S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ICE cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Medinice S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medinice S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Kong King Co Ltd
TWO:3093
|
0.115x |
|
SHIPPING CORPORATION OF INDIA LAND
NSE:SCILAL
|
-0.005x |
|
Tumosan Motor ve Traktor Sanayi AS
IS:TMSN
|
-0.055x |
|
Smart Parking Ltd
AU:SPZ
|
0.132x |
|
MSP Steel & Power Limited
NSE:MSPL
|
0.111x |
|
Remedy Entertainment Oyj
HE:REMEDY
|
0.139x |
|
Favite Inc
TW:3535
|
0.039x |
|
Steamships Trading Company Ltd
AU:SST
|
0.095x |
Annual Cash Flow Conversion Efficiency for Medinice S.A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Medinice S.A from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Medinice S.A (ICE) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł88.12 Million ≈ $24.25 Million |
zł-5.58 Million ≈ $-1.54 Million |
-0.063x | -40.47% |
| 2024-12-31 | zł81.01 Million ≈ $22.30 Million |
zł-3.65 Million ≈ $-1.01 Million |
-0.045x | +56.60% |
| 2023-12-31 | zł33.17 Million ≈ $9.13 Million |
zł-3.45 Million ≈ $-948.66K |
-0.104x | -38.40% |
| 2022-12-31 | zł37.13 Million ≈ $10.22 Million |
zł-2.79 Million ≈ $-767.30K |
-0.075x | -81.17% |
| 2021-12-31 | zł40.58 Million ≈ $11.17 Million |
zł-1.68 Million ≈ $-462.91K |
-0.041x | +78.44% |
| 2020-12-31 | zł16.98 Million ≈ $4.67 Million |
zł-3.26 Million ≈ $-898.30K |
-0.192x | +69.21% |
| 2019-12-31 | zł8.23 Million ≈ $2.26 Million |
zł-5.14 Million ≈ $-1.41 Million |
-0.624x | +3.90% |
| 2018-12-31 | zł2.92 Million ≈ $802.27K |
zł-1.89 Million ≈ $-521.27K |
-0.650x | -25.07% |
| 2017-12-31 | zł3.26 Million ≈ $898.55K |
zł-1.70 Million ≈ $-466.80K |
-0.520x | +87.38% |
| 2016-12-31 | zł151.95K ≈ $41.82K |
zł-625.36K ≈ $-172.11K |
-4.116x | -- |
About Medinice S.A
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technol… Read more